MedPage Today) — Twice-weekly subcutaneous ketamine helped alleviate symptoms of treatment-resistant depression, according to the phase III KADS study.
Among those who received at least one flexible treatment dose (0.5-0.9 mg/kg), ketamine was…
Read More
